Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month High - What's Next?

Key Points

• Maze Therapeutics reached a new 52-week high on Thursday, with shares trading as high as $29.76 and last at $29.35, driven by increased trading volume.
• Several analyst upgrades occurred, with JPMorgan raising their price target to $37.00 and HC Wainwright setting a target of $50.00, indicating strong positive sentiment towards the stock.
• Insider trading activity was noted as Director Richard H. Scheller sold 20,744 shares at a price of $22.37, reflecting ongoing monetary movement within the company.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as $29.76 and last traded at $29.35, with a volume of 21251 shares. The stock had previously closed at $29.26.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MAZE. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an "overweight" rating in a report on Monday, September 29th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 18th. Wedbush started coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $33.83.

Maze Therapeutics Price Performance

The stock has a fifty day moving average of $20.08 and a two-hundred day moving average of $14.58.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

Insider Buying and Selling

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares during the period. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock worth $56,040,000 after acquiring an additional 438,274 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $125,000. Bank of America Corp DE increased its position in shares of Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after acquiring an additional 1,455 shares during the last quarter. Finally, CW Advisors LLC purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $371,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.